GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GH Research PLC (FRA:1KA) » Definitions » Institutional Ownership

GH Research (FRA:1KA) Institutional Ownership : 6.78% (As of Jun. 08, 2024)


View and export this data going back to 2021. Start your Free Trial

What is GH Research Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, GH Research's institutional ownership is 6.78%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, GH Research's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, GH Research's Float Percentage Of Total Shares Outstanding is 28.43%.


GH Research Institutional Ownership Historical Data

The historical data trend for GH Research's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GH Research Institutional Ownership Chart

GH Research Historical Data

The historical data trend for GH Research can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 7.18 6.91 6.91 6.72 6.71 6.60 6.82 6.87 6.80 6.78

GH Research Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


GH Research (FRA:1KA) Business Description

Traded in Other Exchanges
Address
28 Baggot Street Lower, Dublin, IRL, D02 NX43
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Its focus is on developing novel and proprietary 5-Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.

GH Research (FRA:1KA) Headlines

No Headlines